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The immunological effects of continuous veno-venous
haemodiafiltration in critically ill patients
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Background:  Haemodynamic instability is common in septic patients with acute
renal failure. Continuous veno-venous haemodiafiltration (CVVHD) is therefore
used as an alternative to conventional haemodialysis. Haemodialysis is
associated with an activation of the immune system. The aim of the present study
was to test the hypothesis that initiation of CVVHD influences the immune
system with release of proinflammatory cytokines followed by a decrease in
granulocyte activation, as assessed by the expression of adhesion molecules. 
Results:  Fifteen patients were included. Mean Acute Physiology and Chronic
Health Evaluation-2 score before CVVHD was 19 (range 8–27). Mean duration
of CVVHD treatment was 9 days (1–21 days). Tumour necrosis factor-a and
interleukin-8 were detectable in plasma in all patients, whereas interleukin-10
was detectable only in a few patients. Proinflammatory and anti-inflammatory
cytokines were detected in the ultrafiltrate. Large intraindividual and
interindividual variations were demonstrated for all of the immunological
parameters studied. 
Conclusion:  The hypothesis that CVVHD induces the release of
proinflammatory cytokines followed by a decrease in granulocyte activation was
not confirmed in the present study. The heterogeneous group of patients
studied, with different underlying diseases and various durations of illness before
the start of CVVHD, might have contributed to the difficulty in demonstrating the
proposed immunological effect of CVVHD.
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Introduction
Acute renal failure as part of the multiorgan dysfunction
syndrome (MODS) is a severe complication in critically ill
patients. Haemodynamic instability is common in these
patients and is exacerbated by haemodialysis. Continuous
veno-venous haemodiafiltration (CVVHD) is therefore
used as an alternative to conventional haemodialysis.
It is well documented that different types of extracorpo-
real circulation, such as haemodialysis using cuprophane
membranes and cardiopulmonary bypass (CPB), are asso-
ciated with complement activation [1,2]; granulocytopenia
followed by granulocytosis [3], granulocyte activation and
degranulation [3,4]; increased production of proinflamma-
tory and anti-inflammatory cytokines; and increased
acute-phase protein synthesis [5,6]. In fact, CPB elicits a
well defined, temporary, systemic inflammatory response,
which may contribute to organ dysfunction postopera-
tively. CPB using a membrane oxygenator is, however,
used for 1–2h during cardiocirculatory arrest, and thus
differs from CVVHD and haemodialysis. The above men-
tioned effects of haemodialysis are largely due to the use
of cuprophane membranes. With the use of more biocom-
patible membranes, this pronounced activation of the
immune system is not observed. Haemodialysis is used in
(acute and chronic) renal failure for approximately 4h
three to four times a week.
CVVHD is a long-term procedure that is carried out con-
tinuously for several days to weeks. It has recently been
demonstrated [7] that CVVH does not activate the com-
plement system and the intrinsic coagulation pathways.
The immunological effects of CVVHD have, however,
not yet been thoroughly described. Whether it is possible
to perform continuous extracorporal circulation for days or
weeks, even with biocompatible membranes, without
affecting the immune system has not been determined.
The aim of the present study was therefore to test the
hypothesis that initiation of CVVHD in critically ill
CPB = cardiopulmonary bypass; CVVHD = continuous veno-venous haemodiafiltration; FITC = fluorescein-iso-thiocyanate; IL = interleukin;
MaH = mouse against human; MBL = mannose-binding lectin; MODS = multiorgan dysfunction syndrome; TNF = tumour necrosis factor.patients induces an activation of the immune system with
release of proinflammatory cytokines, followed by a
decrease in granulocyte activation, as assessed by the
expression of adhesion molecules. Finally, we investigated
whether proinflammatory and anti-inflammatory cytokines
were removed by the ultrafiltrate.
Material and methods
Patients
The present study was approved by the Regional Ethics
Committee and all patients or their relatives gave their
informed concent. Over a period of 10 months we studied
15 consecutive critically ill patients with acute renal
failure treated with CVVHD. The patients were included
if they developed acute oliguric (<400ml urine/day) or
anuric renal failure as part of MODS and sepsis. The clini-
cal diagnosis of sepsis and MODS were according to the
international consensus definition of sepsis in 1992 [8]. In
all patients, an Acute Physiology and Chronic Health
Evaluation-2 score was calculated on admission to the
intensive care unit and an assessment of the number of
failing organs performed at the time of initiation of
CVVHD. The patients were followed until they died or
were discharged from the intensive care unit.
During CVVHD a combination of haemodialysis and
ultrafiltration is used. This means that molecules may be
removed by diffusion (haemodialysis) as well as by con-
vection (ultrafiltration). In the present study CVVHD was
carried out in the postdilution mode, with a BSM 22
bloodpump and monitor (Hospal, Lyon, France) with a
constant blood flow rate of 100–150ml/min. An AN69
polyacrylonitrile 1.6m2 high-flux membrane (Hospal) was
used in all cases. The AN69 polyacrylonitrile membrane
has a mean pore size of 29Å and a maximum of 55Å, and
is suited for diffusion of small mulecules and for convec-
tion of larger molecules. Filters were used until the filtra-
tion rate was <3ml/min or until a maximum of 2 days of
use. Vascular ascess was provided by internal jugular
silicon twin catheters (Quinton, Gambro, Lund, Sweden).
Daily haemofiltration was tailored to the individual
patient’s needs to maintain urea below 20mmol/l. The
patients were continuously treated with heparin to obtain
an activated clotting time of 150–220s. The dialysate used
was gambrosol 1.5% (calcium 1.75mmol/l, chloride
96mmol/l, magnesium 0.25mmol/l, sodium 132mmol/l,
lactate 40mmol/l; Gambro), the dialysate flow rate was
10–30ml/min and the ultrafiltrate flow rate was
10.4–4.3ml/min.
Laboratory measurements
Arterial blood was sampled in EDTA tubes 1h before the
start of CVVHD; 2, 24 and 48h after the start; and then
every second day until the CVVHD treatment was
stopped, either because of death of the patient or return of
renal function. Patients who were treated with CVVHD
for more than 2 weeks had blood samples taken every
fourth day after the second week. Blood samples were
immediately refrigerated on ice and plasma was isolated
by centrifugation at 1500rpm for 10min. The samples
were subsequently stored at –80°C until they were
assayed. Ultrafiltrate was sampled simultaneously with the
blood samples. The ultrafiltrate samples were also frozen
at –80°C until they were assayed.
Immunological methods
The adhesion/activation molecules on granulocytes and
lymphocyte subpopulations were measured using flow
cytometry and monoclonal antibodies. Heparinized
peripheral blood was incubated with monoclonal antibod-
ies for 15min in the dark at room temperature. The fol-
lowing antibodies were used: anti-CD3-fluorescein-iso-
thiocyanate (FITC) [mouse against human (MaH) IgG1],
anti-CD4-FITC (MaH IgG1), anti-CD8-FITC (MaH
IgG1), CD11a-FITC (MaH IgG1), anti-CD11b-FITC
(MaH IgG1), anti-CD62-FITC (MaH IgG2), anti-CD16-
FITC (MaH IgG1), anti-CD18-FITC (MaH IgG1) and
anti-CD44-FITC (MaH IgG1; all from Dako, Glostrup,
Denmark). Red cells were lysed using ammonium
cloride. Cells were then washed twice with phosphate-
buffered saline and fixed in 1% formalin in phosphate-
buffered saline before being analyzed by flow cytometry
(Coulter Elite, Luton, UK). Both the granulocytes and
lymphocytes were identified on the basis of their forward
and side scatter characteristics. Cells positive for the spe-
cific antigens were scored on the basis of Simultest
control (MIgG1-FITC; Becton-Dickinson, San Jose, Cali-
fornia, USA). The total leucocyte count was determined
using a Coulter Counter S (Coulter Electronics, Luton,
UK) and the differential count was measured automati-
cally (Hematrack Model 360; Geometric Data, Luton,
UK).
The cytokine concentration of tumour necrosis factor
(TNF)-a, interleukin (IL)-8 and IL-10 in plasma and
ultrafiltrate were measured by double-sandwich enzyme-
linked immunosorbent assay. The sensitivities of these
assays for cytokines in plasma were 10–30pg/ml.
Determination of cortisol
The serum cortisol concentration was determined using a
radioimmunoassay technique.
Determination of C3d and C4d
The concentrations of C3d and C4d were determined
using immunoelectrophorese. First an anti-C3d antibody
and anti-C4d antibody gel were produced. Human IgG
was added to activate the serum pool and controls were
made. The specific concentration values of C3d and C4d
were measured by electrophorese. The samples were
water cooled to 16–18°C, and coloured with Coosmassie
Brilliant Blue.
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The complement can be activated via three pathways: the
classical, the alternative and the lectin pathways. The
lectin pathway is initiated by the binding of lectin to
mannose or to carbohydrates from bacteria or viruses. The
concentration of mannose-binding lectin (MBL) was
determined using time-resolved immunofluorometric
assay. A plate was coated with monoclonal antibodies to
MBL and incubated with the samples overnight at 4°C.
Then the samples were washed and Eu-anti-MBL was
added. After washing and overnight incubation the fluo-
rescence were measured using a Wallac 1232 Delfia Fluo-
rometer (Wallac, Turku, Finland).
Statistical analysis
Kolmogorov Smirnof’s test was used to determine whether
the data had a normal distribution. Because only the adhe-
sion molecules were normally distributed, Friedman’s
analysis of variance was used to test for changes within the
group. If Friedman’s test demonstrated a difference, data
were compared with initial values obtained before CVVHD
was started, using Wilcoxon’s rank test. P<0.05 was consid-
ered staistically significant. The results are expressed as
median values (25 and 75% quartiles, or range).
Results
Ten men and five women were included. Eleven patients
developed MODS after surgery, while four patients suf-
fered from medical diseases. The medical diseases
included two cases of pneumonia; one case of endocardi-
tis; and one case of haemolysis, elevated liver enzymes,
low platelets (HELLP) syndrome. The postoperative
patients included two patients with a perforated ulcer, one
with colon cancer, one with pancreas cancer, one with
cholecystolithiasis, three patients with aneurisma of the
abdominal aorta and one trauma patient. Two patients
developed MODS after open heart surgery. One of these
patients was admitted with a congenital heart malforma-
tion, and the other with unstable angina. Mean age was 59
years (range 25–75 years). Mean duration of CVVHD was
9 days (range 1–21 days).
The mean Acute Physiology and Chronic Health Evalua-
tion-2 score before the start of CVVHD was 19.4 (range
8–27). The leucocyte count varied between 4.2 and
26.0×109/l before the start of CVVHD. At the end of the
CVVHD treatment the leucocyte count varied between
2.9 and 31.0×109/l. Initiation of CVVHD influenced
neither the total leucocyte count nor the granulocyte or
lymphocyte count in peripheral blood (Fig. 1).
Before the start of CVVHD the median plasma cortisol
value was 782pg/ml (range 419–1537pg/ml). CVVHD did
not influence the cortisol value, and at the end of the
study a median plasma cortisol of 857pg/ml (range
373–961pg/ml) was measured.
TNF-a was detectable in the plasma of all the patients.
Before the start of CVVHD the median plasma TNF-a
concentration was 70pg/ml (25 and 75% quartiles 38.5
and 93.0pg/ml). CVVHD did not influence the TNF-a
concentration in plasma, and at the end of the study a
median TNF-a level of 66pg/ml (25 and 75% quartiles
41 and 89pg/ml) was measured (Fig. 2). TNF-a was
excreted in the ultrafiltrate by all patients. After 2h
CVVHD the median TNF-a concentrations in the ultra-
filtrate was 12pg/ml (range 0.2–48pg/ml) compared with
12pg/ml (range 0–22pg/ml) at the end of the study
(Fig. 2).
IL-8 was also detectable in the plasma of all of the
patients. Before the start of CVVHD the median IL-8
concentration in plasma was 310pg/ml (25 and 75% quar-
tiles 193 and 640pg/ml). At the end of the study period a
median IL-8 concentration of 260pg/ml (25 and 75% quar-
tiles 112 and 465pg/ml) was measured. CVVHD did not
induce changes in the IL-8 concentration in plasma. IL-8
was detectable in the ultrafiltrate in all the patients. After
2h of CVVHD the median IL-8 concentration in the ultra-
filtrate was 13pg/ml (range 0–52pg/ml) compared with
49pg/ml (range 0–302pg/ml) at the end of the study.
There was no correlation between the concentration of
IL-8 in plasma and ultrafiltrate. This is in accordance with
other investigations [9].
Only in 11 out of 15 patients was IL-10 detectable in the
plasma. The median concentration of IL-10 in the plasma
before CVVHD was 0pg/ml (25 and 75% quartiles 0 and
104pg/ml, range 0–1000pg/ml). IL-10 was excreted in the
ultrafiltrate. Two hours after the start of CVVHD the
median IL-10 concentration in the ultrafiltrate was
180pg/ml (range 0–800pg/ml) compared with 95pg/ml
(range 0–380pg/ml) at the end of the study.
The complement split products C3d, C4d and MBL were
within reference values and were not influenced by the
CVVHD at any time (Fig. 2).
The integrin adhesion molecules CD11a, CD18 and CD
16 on granulocytes were below reference values before the
start of CVVHD, whereas CD11b was above and CD44
was within the normal range. We observed no significant
change in any of these molecules during CVVHD. The
median channel value of the selectin adhesion molecule
CD62L decreased from 416 (25 and 75% quartiles 336 and
491) before the start of CVVHD to 360 (25 and 75% quar-
tiles 340 and 463) and 389 (25 and 75% quartiles 330 and
491) 2 and 24h later (not significant).
The lymphocyte subpopulations CD4 and CD8 were below
reference values before the start of CVVHD, and did not
change during CVVHD. The percentage of CD3+ T lym-
phocytes was 38.2% (25 and 75% quartiles 25 and 44%)
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Figure 1
The concentration of the proinflammatory cytokines tumour necrosis
factor (TNF)-a and interleukin (IL)-8 and the anti-inflammatory cytokine
IL-10 in plasma and ultrafiltrate for eight patients. ­Start of continuous
veno-venous haemodiafiltration.before CVVHD, but increased significantly to 44.8% (25 and
75% quartiles 35 and 50%) after 2h of CVVHD (P<0.05).
Discussion
We did not observe any increased production of proinflam-
matory or anti-inflammatory cytokines during CVVHD,
which is in contrast to the increased production of cytokines
that occurs after CPB and haemodialysis [5,6]. The pres-
ence of the proinflammatory cytokines TNF-a and IL-8 in
the peripheral blood of all septic patients and the presence
of the anti-inflammatory cytokine IL-10 in some of the
patients are in accordance with findings from other investi-
gations [9,10]. The present study shows that not only the
proinflammatory cytokines, but also the antiinflammatory
cytokines are excreted in the ultrafiltrate. The amount of
TNF-a excreted in the ultrafiltrate varies widely. Bellomo
et al [11] observed a daily excretion of TNF-a of 15.9mg
with CVVHD, whereas Sanders et al [12] measured an
excretion of only 1.7mg/48h with continuous arteriovenous
haemofiltration. Although the cytokines in the present
study were excreted at low concentrations in the ultrafil-
trate, the plasma concentrations did not decrease. This is in
accordance with the findings of Bellomo et al [11] and
Sanders  et al [12], and those of a study by Tønnesen et al [9]
with continuous arteriovenous haemofiltration. In addition
to ultrafiltration, the polyacrylonitrile filters might adsorb
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Figure 2
The number of granulocytes, C3d in plasma, and the adhesion
molecules CD62L and CD11b on granulocytes in relation to
continuous veno-venous haemodiafiltration (CVVHD) for eight patients.
The values are an index of the initial value before CVVHD. ­Start of
CVVHD.not only complement mediators [2], but also cytokines,
expecially TNF and IL-6 [13]. The lack of a decrease in
the plasma levels of cytokines during CVVHD might be
due to a minor activation of the extracorporeal circulation
that is neutralized by adsorption and excretion into the
ultrafiltrate. So far, however, the clinical significance of the
limited removal of proinflammatory and anti-inflammatory
cytokines in the ultrafiltrate remains unknown.
If the white blood cells, especially the granulocytes, are
activated they will increase the expression of adhesion
molecules on their surface. The adhesion molecules are
necessary for the adhesion and migration through
endothelium into the tissues of activated cells. Two fami-
lies of adhesion molecules are necessary for the adhesion
and migration of granulocytes through endothelium into
tissues, namely the integrin and the selectin family. The
CD11a–c/CD18 adhesion molecules are the most impor-
tant integrins, whereas CD62L is the most important
member of the selectin family. CD44 is the most impor-
tant member of a third adhesion molecule family termed
the homing-associated cell adhesion molecules. Because
the adhesion molecules enable activated cells to migrate
into tissues, they play a key role in the development of
adult respiratory distress syndrome and MODS. In addi-
tion, any major activation of the granulocytes in particular
will be reflected in a change in the expression of adhesion
molecules on their surface.
Several studies have demonstrated an increased expres-
sion of CD18 and CD11b adhesion molecules on granulo-
cytes after 15–30 min of haemodialysis, whereas the
expression of CD62L on granulocytes was decreased.
After 3h of haemodialysis the granulocyte adhesion mole-
cules were nearly normalized [14,15]. To our knowledge
the effect of CVVHD on the important adhesion mole-
cules CD11a, CD11b, CD18 and CD44 has not been
investigated before. We did not observe any significant
changes in the adhesion molecules on granulocytes, but
only a tendency to a decrease in CD62L levels 2h after
the start of CVVHD. This is in accordance with a recent
study by Kellum et al [10] who failed to demonstrate any
significant changes in soluble L-selectin during CVVHD.
The percentage of CD3+ T lymphocytes increased signifi-
cantly 2h after the start of CVVHD. In haemodialyses
patients an increased propotion of CD3+ T lymphocytes
has also been detected [16]. The absence of significant
changes in the other lymphocyte subpopulations and in
the number of natural killer cells is in contrast to findings
with haemodialysis. During haemodialysis a decline in the
number of natural killer cells and an increase in the pro-
portion of CD4+ lymphocytes have been observed [17].
The initiation of CPB and haemodialysis with use of
cuprophane membranes is associated with granulocyto-
penia followed within hours by granulocytosis [3,18]. In
contrast, we did not observe any significant changes in the
number of granulocytes or lymphocytes in peripheral
blood during CVVHD. This may indicate that the granu-
locytes were activated to lesser extent with CVVHD than
they are with CPB and heamodilaysis.
The elevated serum cortisol level in these critically ill
patients is in accordance with that found in other investi-
gations [19]. The serum cortisol level did not increase
during CVVHD, however. Thus no endocrine stress
response was elicited by CVVHD.
Extracorporeal circulation in the form of CPB activates the
complement system [1]. Several studies have also demon-
strated an activation of the complement system during
haemodialysis, although to a lesser degree. Andreassen et
al [20] measured complement factors in the ultrafiltrate
and a reduction in C3a and C3b in the blood during
haemofiltration. In addition, it has been shown [2] that
complement factors are adsorped into the polyacrylonitrile
filter used for CVVHD. In the present study we observed
neither an activation of the complement system, nor a
decrease in the levels of complement factors in the blood.
With the polyacrylonitrile filters a minor activation of the
complement system might be neutralized by adsorption
into the filter and excretion in the ultrafiltrate.
The large intraindividual and interindividual variation in
the measured immunological parameters has also been
observed in other studies [10,11]. The hypothesis that
CVVHD induces an activation of the immune system with
release of proinflammatory cytokines followed by a
decrease in granulocyte activation as assessed by the
expression of adhesion molecules was not confirmed in
the present study. The heterogenic patient population,
with different underlying deseases and various durations
of illness before the start of CVVHD, might have con-
tributed to the large variation in the measured immuno-
logical parameters.
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